165 related articles for article (PubMed ID: 16254324)
41. Decreased in vitro type 1 immune response against coxsackie virus B4 in children with type 1 diabetes.
Skarsvik S; Puranen J; Honkanen J; Roivainen M; Ilonen J; Holmberg H; Ludvigsson J; Vaarala O
Diabetes; 2006 Apr; 55(4):996-1003. PubMed ID: 16567521
[TBL] [Abstract][Full Text] [Related]
42. [Study of levels of antibody against coxsackievirus B in different adults in Changsha area].
Xie M; Tan H; Pu P
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):128-30. PubMed ID: 11938768
[TBL] [Abstract][Full Text] [Related]
43. Antibody-mediated enhancement of the rate, magnitude, and responsiveness of vesicular stomatitis virus induced alpha interferon production.
Green DS; Lum T; Mullins BT; Green JA
J Med Virol; 2008 Sep; 80(9):1675-83. PubMed ID: 18649334
[TBL] [Abstract][Full Text] [Related]
44. Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL-1 beta, and IL-6 in human monocytes.
Henke A; Mohr C; Sprenger H; Graebner C; Stelzner A; Nain M; Gemsa D
J Immunol; 1992 Apr; 148(7):2270-7. PubMed ID: 1312105
[TBL] [Abstract][Full Text] [Related]
45. A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells.
Cong Z; Wan M; Wu X; Wang L; Hu X; Yang F; Bao M; Zhang X; Chen J; Wang L; Yu Y
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):26-34. PubMed ID: 17608709
[TBL] [Abstract][Full Text] [Related]
46. Enterovirus infection induces cytokine and chemokine expression in insulin-producing cells.
Nair S; Leung KC; Rawlinson WD; Naing Z; Craig ME
J Med Virol; 2010 Nov; 82(11):1950-7. PubMed ID: 20872723
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibodies to equine interferon-alpha (IFN-alpha): new tools to neutralize IFN-activity and to detect secreted IFN-alpha.
Wagner B; Hillegas JM; Flaminio MJ; Wattrang E
Vet Immunol Immunopathol; 2008 Oct; 125(3-4):315-25. PubMed ID: 18586327
[TBL] [Abstract][Full Text] [Related]
48. A neutralizing monoclonal antibody against Coxsackievirus B4 cross-reacts with contractile muscle proteins.
Beisel KW; Srinivasappa J; Olsen MR; Stiff AC; Essani K; Prabhakar BS
Microb Pathog; 1990 Feb; 8(2):151-6. PubMed ID: 2161486
[TBL] [Abstract][Full Text] [Related]
49. Human milk can neutralize Coxsackievirus B4 in vitro.
Sane F; Alidjinou EK; Kacet N; Moukassa D; Charlet C; Ebatetou-Ataboho E; Ngoulou W; Badia-Boungou F; Romond MB; Hober D
J Med Virol; 2013 May; 85(5):880-7. PubMed ID: 23408519
[TBL] [Abstract][Full Text] [Related]
50. CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis.
Han B; Jiang H; Liu Z; Zhang Y; Zhao L; Lu K; Xi J
Can J Cardiol; 2012; 28(2):239-44. PubMed ID: 22336520
[TBL] [Abstract][Full Text] [Related]
51. Salivary anti-coxsackievirus-B4 neutralizing activity and pattern of immune parameters in patients with type 1 diabetes: a pilot study.
Nekoua MP; Yessoufou A; Alidjinou EK; Badia-Boungou F; Moutairou K; Sane F; Hober D
Acta Diabetol; 2018 Aug; 55(8):827-834. PubMed ID: 29774468
[TBL] [Abstract][Full Text] [Related]
52. Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3.
Yang L; He D; Tang M; Li Z; Liu C; Xu L; Chen Y; Du H; Zhao Q; Zhang J; Cheng T; Xia N
Clin Vaccine Immunol; 2014 Mar; 21(3):312-20. PubMed ID: 24391137
[TBL] [Abstract][Full Text] [Related]
53. Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene.
Tong L; Lin L; Zhao W; Wang B; Wu S; Liu H; Zhong X; Cui Y; Gu H; Zhang F; Zhong Z
Intervirology; 2011; 54(5):268-75. PubMed ID: 21242657
[TBL] [Abstract][Full Text] [Related]
54. Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin.
Ashton MP; Eugster A; Walther D; Daehling N; Riethausen S; Kuehn D; Klingel K; Beyerlein A; Zillmer S; Ziegler AG; Bonifacio E
Sci Rep; 2016 Sep; 6():32899. PubMed ID: 27604323
[TBL] [Abstract][Full Text] [Related]
55. T-Cell reactivity to the P2C nonstructural protein of a diabetogenic strain of coxsackievirus B4.
Varela-Calvino R; Sgarbi G; Arif S; Peakman M
Virology; 2000 Aug; 274(1):56-64. PubMed ID: 10936088
[TBL] [Abstract][Full Text] [Related]
56. Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis.
Shen Y; Xu W; Chu YW; Wang Y; Liu QS; Xiong SD
J Virol; 2004 Nov; 78(22):12548-56. PubMed ID: 15507642
[TBL] [Abstract][Full Text] [Related]
57. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route.
Bopegamage S; Borsanyiová M; Vargová A; Petrovicová A; Benkovicová M; Gomolcák P
Acta Virol; 2003; 47(4):245-51. PubMed ID: 15068380
[TBL] [Abstract][Full Text] [Related]
58. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells.
Ronni T; Sareneva T; Pirhonen J; Julkunen I
J Immunol; 1995 Mar; 154(6):2764-74. PubMed ID: 7876547
[TBL] [Abstract][Full Text] [Related]
59. Selective production of interferon-alpha subtypes by cultured peripheral blood mononuclear cells and lymphoblastoid cell lines.
Greenway AL; Overall ML; Sattayasai N; Rowley MJ; Hertzog PJ; McMullen GL; Cheetham BF; Marzuki S
Immunology; 1992 Jan; 75(1):182-8. PubMed ID: 1537595
[TBL] [Abstract][Full Text] [Related]
60. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance.
Maisch B; Bauer E; Cirsi M; Kochsiek K
Circulation; 1993 May; 87(5 Suppl):IV49-65. PubMed ID: 8485834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
